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Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.05.011Objectives: This study examined the feasibility of thoracoscopic wedge resection
and radiotherapy for clinical T1 lesions in patients with compromised cardiopul-
monary status.
Methods: In this phase II, prospective, multicenter, cooperative group trial,
high-risk patients had one or more of the following risk factors: forced expira-
tory volume in 1 second less than 40%, carbon monoxide diffusing capacity in
lung less than 50%, and maximum oxygen consumption less than 45 mm Hg.
Patients underwent video-assisted wedge resection followed by local (56 Gy)
radiotherapy. The primary end point was the proportion of patients whose
disease could be completely resected and who received radiotherapy without
treatment complications.
Results: Between September 1995 and September 1999, a total of 65 patients
were accrued, of which 58 were eligible (52% male, median age 69 years).
Pathologic staging resulted in upgrading to T2 or greater in 16 of 58 cases (28%)
and in reassessment as benign in 10 of 58 cases (17%). Conversion to thora-
cotomy was required in 10 cases (17%), including 1 of 10 benign T1-size lesion
(10%), 4 of 35 non–small cell lung cancer T1 lesions (13%), and 5 of 14
non–small cell lung cancer T2 lesions (31%). Resection margins were positive
in 5 patients: 6% of T1 and 23% of T2. Surgery was aborted in 2 cases (3.5%),
and operative mortality was 4%. Overall operative failure rates of video-assisted
wedge resection were 20% for benign T1-size lesions, 22% for T1 non–small
cell lung cancer, 21% for all T1 lesions, 50% for T2 non–small cell lung cancer,
and 29% for all lesions in this study (clinical T1). Prolonged air leaks occurred
in 10%, pneumonia in 6%, and respiratory failure in 4%. Thirty-one patients
were eligible for radiotherapy; 3 of them refused, and 1 died before treatment.
Among the 28 patients who received radiotherapy, severe dyspnea was noted in
3 patients (11%) and moderate pneumonitis in 4 (14%).
Conclusions: Clinical staging in high-risk patients is often inaccurate (45% differ-
ence from pathologic staging). Intention to treat clinically staged T1 disease by
video-assisted wedge resection is associated with a high failure rate. Pathologically
staged T1 lesions can be successfully resected in 75% of cases; however, narrow
resection margins remain a concern.
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TSMajor surgical resection (lobectomy) hasbeen proved to be the best therapeuticmodality for T1 non–small cell lungcancer (NSCLC).1 Though only a fewsingle-center studies have examined therole of limited resection in treating
high-risk patients, several uncontrolled studies reported during
the last decade have suggested a potential benefit of limited
surgical resection (wedge resection and segmentectomy) alone
or with adjuvant radiotherapy in treating patients with com-
promised cardiopulmonary status.2,3These studies suggest that
limited lung resection in select groups of NSCLC patients is
safe and effective.
The emergence of innovative surgical technologies that
permit the performance of surgical procedures by less-
invasive endoscopic techniques have gained increasing ac-
ceptance by surgeons. Such treatments are sought by many
patients, who are lured by the potential for a faster recovery
with less pain and morbidity. Thoracic surgeons have rap-
idly adopted video-assisted thoracoscopic wedge resection
(VAR) techniques for the treatment of lung cancer, but
without proper validation. Despite evidence for some early
postoperative advantages, several studies have failed to
show substantial benefits of endoscopic and other minimally
invasive cancer resection techniques. In fact, innovative
surgical technology in general has not been subjected to the
same rigor of clinical trials required for other cancer ther-
apies. This study was designed to evaluate the feasibility of
treating patients with poor cardiopulmonary status and pe-
ripheral T1 NSCLC with VAR and local radiotherapy. The
study (The Cancer and Leukemia Group B [CALGB] 9335)
was conducted as a phase II, multi-institutional, cooperative
group trial.
Patients and Methods
Objectives
The primary objective of CALGB 9335 was to determine
the feasibility of treating patients with cardiopulmonary
dysfunction and T1 peripheral NSCLC by VAR and radio-
therapy. The basis for determining feasibility and safety was
the proportion of patients who could not have complete
resection with video-assisted thoracoscopic technology or
who had any of the following complications: (1) major
operative complications occurring within 30 days after sur-
gery, including death, myocardial infarction, and cardiac or
respiratory failure necessitating mechanical ventilation for
more than 72 hours; (2) delayed complications related to
surgery or radiotherapy (within 6 months), including pro-
gressive dyspnea, hypoxia or hypercarbia, and decline in
measured lung functions; (3) conversion to thoracotomy for
any reason, including extent of tumor, adhesions, technical
difficulty, and complications; and (4) positive resection
margins at completion of final resection. Secondary objec-
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incidence of locoregional recurrence among high-risk pa-
tients with T1 peripheral NSCLC treated by VAR and
radiation therapy, (2) to describe pattern of survival and
disease-free survival in high-risk patients treated with VAR
and radiotherapy, (3) to determine the technical feasibility
of ipsilateral lymph node sampling and complete resection
with VAR, (4) to describe the rate and causes of conversion
to open thoracotomy, (5) to describe the short- and long-
term complications associated with VAR, and (6) to de-
scribe the toxicity associated with adjuvant radiotherapy
after VAR.
Inclusion and Exclusion Criteria
Patients were required to fulfill the following criteria to be
eligible: (1) tumor characteristics of single T1-size lung
nodule on computed tomography (CT) located peripherally
and judged to be surgically accessible for thoracoscopic
resection by the surgeon; and (2) patient characteristics of
forced expiratory volume in 1 second of less than 40%,
carbon monoxide diffusing capacity in lung of less than
50%, maximum oxygen consumption of less than 15 mL/
(kg · min), oxygen requirement, or arterial carbon dioxide
level of more than 45 mm Hg. In addition, the following
were considered exclusion criteria: (1) evidence of distant
metastasis, pleural effusion, or N2 disease by CT scan, with
patients with lymph nodes larger than 1 cm on CT scan
required to undergo mediastinoscopy to role out lymph node
metastasis; (2) previous chest radiotherapy; and (3) previous
cancer other than nonmelanoma skin cancer and in situ
cervical cancer, with patients with other cancer but more
than 5-year disease-free interval considered eligible.
Schema of Protocol
Patients meeting selection criteria were registered and sub-
jected to VAR of the suspect nodule. After complete resec-
tion and pathologic documentation of T1 NSCLC, patients
were reregistered and subjected to radiation therapy (56 Gy)
per protocol. Those with incomplete resection or positive
resection margins underwent radiation therapy with a higher
dose of 66 Gy.
Technique of VAR
Preparation, positioning of patients and method of admin-
istering anesthesia were left to the discretion of the treating
team. Wedge resection was to be performed with endosta-
plers or other means under indirect thoracoscopic vision,
either totally endoscopically or with the addition of a work-
ing incision not exceeding 8 cm and without the use of
retractors. Systematic attempt at intraoperative thoraco-
scopic identification and sampling of ipsilateral lymph
nodes before commencement of resection was incorporated
l 2005
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techniques in performing adequate lymph node staging.
Intraoperative pathologic examination of frozen sections
of resection margins was required. Additional resection was
to be performed if margins were shown to have malignant
cells, unless this was not feasible for technical or other,
patient-related reasons.
Technique of Radiotherapy
A radiation oncologist saw patients at re-registration time,
and radiation treatment started between 14 and 56 days after
surgery. Patients with complete resection received a total of
56 Gy in 28 fractions of 2.0 Gy/d and 5 fractions/wk. Those
with incomplete resection were treated with a total dose of
66 Gy in 33 fractions of 2.0 Gy in 5 fractions/wk. The target
volume was defined by the staple line or clip markings with
an additional 2 cm margin, to a maximum total field of 7 
7 cm for completely resected tumors and one of 8  8 cm
for incompletely resected tumors. The prescription point
was the center of the target volume.
Statistical Methods
The primary end point of CALGB 9335 was the proportion
of patients with cardiopulmonary dysfunction and a single
peripheral T1 N0 NSCLC or suspected lung cancer who
could be completely resected and receive radiotherapy with-
out acute operative complication or delayed complications
from the resection or radiotherapy. The study hypothesis
assumed that the treatment regimen was unacceptable if
failure, defined as inability to completely resect tumor or
presence of complications, occurred in 30% or more of
patients, whereas the regimen was acceptable if this propor-
tion was 15% or less. To estimate the unknown proportion
of failures, p, it was necessary to define and estimate the
following unknown parameters: P1, the proportion of pa-
tients with acute postoperative and intraoperative complica-
tions or incomplete resection, and P2, the proportion of
patients with delayed complications among those with com-
plete resection and have no acute complications. This pro-
portion is the conditional probability of delayed complica-
tions for a patient who underwent complete resection
without acute complications.
The numbers of patients on which estimates of P1 and P2
are based differ because of patient withdrawal, ineligibility
after resection, occurrence of acute postoperative complica-
tions, and incomplete resections. The denominator of P1
was all patients accrued to this study, including those who
were subsequently discovered to be ineligible according to
histologic criteria. The denominator of P2 was the number
of patients who received radiation after complete resection
without acute operative complications. With an accrual goal
of 65 patients, simulation studies were conducted that
showed that the study design had a type I and II error rate
The Journal of Thoraciof 10% under the following assumptions: (1) 10% to 20% of
patients who undergo resection would withdraw before ra-
diotherapy or not be eligible for radiotherapy, and (2) the
proportion of patients who would not undergo radiotherapy
after complete resection without acute operative complica-
tions was 20%.
The product limit estimator developed by Kaplan and
Meier was used to describe the survival and failure-free
survival from study entry and after surgery for patients
enrolled in CALGB 9335. Survival was defined as time
from study entry until death, whereas survival after surgery
was defined as the time between surgery and death. Failure-
free survival and failure-free survival after surgery were
computed from study entry or time of surgery until initial
failure (death, disease progression, or relapse).
Analyses were based on all data available as of February
2002.
Results
Between September 1995 and September 1999, a total of 65
patients were accrued, consistent with the target. CALGB
institutions accrued 54 patients and The Eastern Coopera-
tive Oncology Group institutions accrued 11 patients. Of the
65 patients accrued, 7 patients were retrospectively deter-
mined by the study chair to have been ineligible to enroll in
CALGB 9335. Reasons for ineligibility included prestudy
chest images confirming T2 disease in 3 patients, preoper-
ative workup of suspected mediastinal involvement in 1
patient, N2 or N3 lymph nodes in 2 patients, and suspected
extensive local thoracic disease before surgery in 1 patient.
These 7 patients are therefore excluded from all analyses.
Among the remaining 52 patients, 58% were male, the age
median was 69 years (49-82 years), and 77% had a perfor-
mance status of 0 or 1. The median forced expiratory
volume in 1 second for all patients was 37% predicted,
carbon monoxide diffusing capacity in lung was 44% pre-
dicted, the maximum oxygen consumption was 13 mL/(kg ·
min), and 10% of patients were oxygen dependent.
Table 1 summarizes the operative success or failure of
VAR for all patients and for each of the specific pathologic
stages. Patients with benign T1-size lesions had an 80%
success rate (8/10). The T1 NSCLC success rate was 78%
TABLE 1. Operative outcomes in relation to pathologic
staging
Total Failure Success
Benign T1-size lesions 10 2 (20%) 8 (80%)
T1 NSCLC 32 7 (22%) 25 (78%)
All T1 42 9 (21%) 33 (79%)
T2 and other 16 8 (50%) 8 (50%)
Total 58 17 (29%) 41 (71%)(25/32), whereas that for all T1 lesions was 79% (33/42).
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success rate of 50% (8/16). The total success rate for all
VAR procedures in this study was 71% (41/58). Table 2
describes the reasons for conversion to open thoracotomy or
abortion of surgery altogether and its association with in-
crease in staging to T2 or higher.
Conversion to thoracotomy occurred in 10 cases (17%),
including 1 patient with benign T1-size disease (10%), 4
patients with T1 NSCLC (13%), and 5 patients with T2
NSCLC (31%). Resection margins were found to be posi-
tive in 5 patients (8.6%): 2 patients with T1 NSCLC (6%)
and 3 patients with T2 NSCLC (19%). Surgery was aborted
in 2 cases, and 2 other patients died early after the operation.
Table 3 describes the relationship of pathologically de-
termined tumor size to the width of resection margins. A
wide resection margin of 1 cm or more was present in 7 of
9 patients with benign T1-size lesions (78%), in 14 of 32
patients with T1 NSCLC lesions (44%), and in 5 of 15
patients with T2 NSCLC and other lesions (33%). Overall,
only 46% of patients undergoing VAR in this study had a
surgically wide (1 cm) resection margin. VAR was per-
formed equally on both sides (52% on right, 48% on left).
The numbers of incisions used per procedure were 2 in 9%
of all cases, 3 in 79%, and 4 in 11%. Lung deflation
permitting ease of exposure was partial in 38% of cases, full
in 55%, and not performed in 4%. Adhesions were absent in
50%, of cases minimal in 21%, moderate in 21%, and
extensive in 7%. Pulmonary lobes were reported to be
anatomically separate in 59% of patients and not separate in
34%.
Compliance with systematic ipsilateral lymph node sam-
pling was rather poor in this study. Only lymph nodes R4,
TABLE 2. Reasons for failure and relationship to operative
Patient T2 pathologic stage
60446 Yes
61734
63197
63567 Yes
66724
66767
66843
67247
67953 Yes
68588 Yes
69013
69745 Yes
71029 Yes
71744
71763
73901 Benign 
73988 BenignR7, and R13 were explored, and only in a total of 21
816 The Journal of Thoracic and Cardiovascular Surgery ● Apripatients. Because the accessibility of lymph nodes was
limited, no meaningful data could be additionally gained
from attempting to sample these lymph nodes. Sampling
ranged from 2% for R13 lymph node station to 47% for R4
and R7 lymph nodes stations. Nonanatomic wedge resection
was performed with automated stapler devices in 89% of
procedures, cautery dissection in 14%, and laser dissection
in 2%. Intraoperative bleeding was noted to be absent in
57% of VAR procedures, minimal in 41%, and moderate in
2%. Surgeons used only one chest tube for drainage in most
cases (73%) and 2 tubes in 27% of cases. The duration of
VAR procedures was a median of 100 minutes, ranging
between 40 and 255 minutes.
Postoperative complications (Table 4) were low, with 2
deaths from cardiorespiratory failure (4%), respiratory fail-
ure requiring mechanical ventilation in 4%, pneumonia in
6%, arrhythmia in 6%, and prolonged air leak in 10%. Of
the total number of patients registered in the study, 32
patients were found to have pathologically staged T1
NSCLC. Three patients refused radiotherapy, and another
died of underlying lung disease before commencement of
radiotherapy. Twenty-eight patients completed radiother-
apy. Toxicity from this treatment is reported in Table 5.
As of October 2001, survival of patients with pathologic
T1 disease was determined from the time of surgical resec-
tion until death. With 18 of the 31 patients dead, the median
survival after surgery was 32 months (95% confidence
interval 4-20.7).
Failure-free survival after surgery was determined from
the time of surgery until first failure (relapse, disease pro-
gression, or death). With 18 of 31 patients having failure,
the median failure free survival was 30.5 months (95%
ging
erted Problem
Positive margins after resection
ort Extensive adhesions
es Exposure, tumor rupture
es Large tumor, positive margins
es Localization
es Exposure, adhesions
es Adhesions, bleeding
Positive margins after resection
es Exposure, localization
es Large tumor, exposure, positive margins
ort Deep tumor
es Secondary malignancy detected
es Large tumor, technical difficulties
Positive margins after resection
Intraoperative death, respiratory failure
Intraoperative bleeding, died day 2
es Extensive adhesionssta
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Y
Y
Y
Y
Y
Y
Y
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Y
Yconfidence interval 4-13.4).
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staged T1 NSCLC, with 16 of 28 patients dead, was 27.2
months (95% confidence interval 4-17.2). Median failure-
free survival after radiotherapy completion, with 16 of 28
patients dead, was 26.8 months (95% confidence interval
4-9.93).
Discussion
VAR has been advocated as an attractive noninvasive ap-
proach to limited resection of lung cancer, particularly for
patients with limited cardiopulmonary reserve who are
feared to be unable to tolerate major lung resection. Until
now there have not been any prospective examination of the
advantages and limitations of applying new technology such
as video-assisted techniques to the treatment of lung cancer.
This multi-institutional study was conducted by surgeons
who were required to show proficiency in thoracoscopic
techniques. It exposes some serious limitations of the inten-
tion to treat high-risk patients with T1 NSCLC by means of
VAR techniques.
First, it is clear from this study that preoperative clinical
staging seriously overestimates or underestimates the extent
of local disease. This may in part be attributable to the
heterogeneity of underlying lung disease in this predomi-
nantly severely emphysematous study population. Addition-
ally, this limitation may reflection the quality of CT scans
used in the 1990s. Application of VAR in the treatment of
patients with lesions pathologically proved to be larger than
T1 was associated with 29% risk of failure from conversion,
abortion of thoracotomy, or incomplete resection.
On the other hand, this study suggests that for high-risk
patients with confirmed T1 NSCLC it is possible to use
TABLE 3. Pathologic staging and effect on width of surgic
Margins Benign
Widely resected 7 (78%) 1
Narrowly resected 2 (22%) 1
Positive margins 0 (0%)
Unknown 0 (0%)
TABLE 4. Postoperative complications of VAR
Complication %
Surgical death 4
Postoperative fever 14
Air leak 10
Pneumonia 6
Respiratory failure 4
Arrhythmia 6
Myocardial infarction 0VAR with a low surgical morbidity. However, even patients
The Journal of Thoraciwith pathologically confirmed T1 disease are noted to be at
risk for resection margins close to (1 cm) from tumor
margins when VAR is used. Thus there is a potentially
increased risk of locoregional recurrence.
Although visualization and intraoperative surgical resec-
tion proceed uncomplicated in most cases, we are concerned
with the limited ability to inspect and sample intrathoracic
lymph nodes. This potential limitation of thoracoscopy in
staging the locoregional extent of tumors, including ipsilat-
eral lymph node status, may not have much impact on
patients with limited life expectancy from cardiopulmonary
dysfunction. However, it may be a serious consideration in
the role of thoracoscopy in patient with a physiologic status
that permits major resection or further adjuvant therapy.
Considering the high technical failure rate of thoraco-
scopic resection for all patients with clinically staged T1
lung cancer, including those who were later determined to
have T2 or greater disease, one must conclude that VAR in
its current form should not be considered the preferred
treatment for patients with clinical T1 lung cancer. Improve-
ments in imaging techniques for precise determination of
tumor size and better VAR technology to permit wider
resection margins may render thoracoscopic resection more
acceptable in the future. Currently, however, we conclude
that VAR is a compromising procedure that must be used
only in compromised situations. Risks must be clearly in-
dicated to patients. In the absence of better therapeutic
alternatives, VAR may be advocated for the treatment of
high-risk patients, patients who already have advanced un-
derlying lung disease and thus a more limited survival
expectance than the population at large, with an effort made
to obtain wider resection margins. Consideration in the
future must be given to examining the role of radiotherapy
modalities alone or surgical resection, which would permit
esection margins
T2 and other All (n  56)
) 5 (33%) 26 (46%)
) 6 (40%) 22 (39%)
) 2 (13%) 4 (7%)
) 2 (13%) 4 (7%)
TABLE 5. Complications associated with radiotherapy af-
ter VAR
Mild Moderate Severe
Dyspnea 11% 11%
Pneumonitis 4%
Neurologic 4% 4%
Soft tissue 11%al r
T1
4 (44%
4 (44%
2 (3%a wider resection margin.
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ing persons and institutions participated in the study: Donald
Burney (Secc-Moses, Greensboro, NC); Robert Cameron
(SWOG, LosAngeles, Calif); A. Alan Conlan (University of
Mass, Worcester, Mass); Malcolm Decamp (Cleveland Clinic,
Cleveland, Ohio); Todd Demmy (University of Missouri, Ellis
Fischel, Columbia, Mo); Kemp Kernstine (University of Iowa,
Iowa City, Iowa); Leslie Kohman (SUNY Upstate, Syracuse,
NY); Mark Krasna (University of Maryland, Baltimore, Md);
Rudy Lackner (Long Island Jewish Medical Center, Hyde Park,
NY); Thomas Lad (VAMC, Chicago, Ill); Michael Maddaus
(University of Minnesota, Minneapolis, Minn); Stephen Myers
(SUNY Upstate, Hyde Park, NY); Keith Shulman (Louis A.
Weiss Memorial Hospital, Chicago, Ill); Joshua Sonett
(Baltimore VAMC, Baltimore, Md); David Sugarbaker818 The Journal of Thoracic and Cardiovascular Surgery ● ApriReferences
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